RESOLVING THE LEDGER
This is one outlet's own report from The Motley Fool — the article as it was filed. Other outlets are covering the same event; open the full story to compare every source side by side.
See the full story · 10 sources
A late-stage trial that combined a messenger ribonucleic acid (mRNA) shot jointly developed by Moderna (NASDAQ:MRNA) and Merck with Merck’s Keytruda yielded strong results in what's being viewed as a potential game-changing cancer treatment.
The Phase 3 trial enrolled over 1,100 patients with melanoma whose tumors had been completely removed by surgery.
Patients who received the personalized vaccine alongside Keytruda went longer before their cancer returned, and longer before it spread to distant parts of the body, than patients who received Keytruda alone.
Continue reading
AIPROPX is an independent multi-source news index — we track, compare, and connect coverage from across the web into one place you won't find anywhere else.